Tag: Eradication therapy

After successful *Helicobacter pylori* eradication, over 90% of uncomplicated duodenal ulcers can heal, often making long-term acid suppression unnecessary. The question of whether to continue a PPI after *H. pylori* treatment is complex and depends heavily on the underlying condition and its severity.

According to a 2018 meta-analysis, primary resistance rates of *H. pylori* to levofloxacin were found to be above 15% in most WHO regions, with some areas having even higher levels. The question, "**Is H. pylori resistant to levofloxacin?**" is critically important for determining effective treatment strategies in an era of rising antibiotic resistance.

In laboratory settings, meropenem has been shown to have bactericidal activity against *Helicobacter pylori*. However, this finding in a petri dish does not equate to effective treatment in a patient, prompting the important question: **Does meropenem cover H pylori?**.

The worldwide prevalence of *H. pylori* infection is estimated to be as high as 50%, yet a significant percentage of first-line treatments fail, largely due to antibiotic resistance. In this context, the fluoroquinolone antibiotic **levofloxacin** has emerged as a valuable component in more advanced strategies to eradicate the bacteria.

Over half the world's population may have an *H. pylori* infection at some point in their lives, with most cases occurring in childhood. Left untreated, this bacterial infection can lead to chronic gastritis, peptic ulcers, and even increase the risk of gastric cancer. The primary question for affected individuals is: **what kills *H. pylori*?**